NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $17.62 -0.06 (-0.34%) As of 09/18/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.37▼$17.9550-Day Range$17.28▼$24.1352-Week Range$12.99▼$25.59Volume5.18 million shsAverage Volume1.36 million shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$42.30Consensus RatingModerate Buy Company Overview Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for cancer and other serious diseases. The company’s research has centered on medicines that target disease-driving biological pathways, including genetically defined forms of leukemia and immune-related conditions. Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved by the U.S. Food and Drug Administration for certain adults and children with relapsed or refractory acute leukemia involving a KMT2A translocation. The company continues to evaluate revumenib in additional leukemia settings and in combination with other cancer treatments. Syndax has also developed axatilimab, a monoclonal antibody designed to inhibit the colony-stimulating factor 1 receptor, or CSF-1R. The therapy has been investigated for chronic graft-versus-host disease and other diseases involving abnormal immune-cell activity and tissue fibrosis. Syndax is headquartered in Waltham, Massachusetts, and its development and commercial activities are primarily focused on the United States while it pursues broader opportunities for its medicines. Michael A. Metzger serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreSNDX MarketRank™: Syndax Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 267th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSyndax Pharmaceuticals has a consensus price target of $42.30, representing about 140.1% upside from its current price of $17.62.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 23.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.70% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 19.65, which indicates bearish sentiment.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 5.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.88 News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest8 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $784,770.00 in company stock.Percentage Held by Insiders4.80% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSyndax Pharmaceuticals has minimal institutional ownership at this time.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNDX Stock News HeadlinesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 14, 2026 | americanbankingnews.comHead-To-Head Review: Aligos Therapeutics (NASDAQ:ALGS) and Syndax Pharmaceuticals (NASDAQ:SNDX)September 11, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comSyndax Announces Participation in September Investor ConferencesSeptember 1, 2026 | globenewswire.comSyndax (SNDX) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comHow Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) InvestorsAugust 8, 2026 | finance.yahoo.comSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.01 on January 1st, 2026. Since then, SNDX stock has decreased by 16.1% and is now trading at $17.62. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Tuesday, August, 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.10. The company's quarterly revenue was up 91.8% compared to the same quarter last year. Read the conference call transcript. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Top institutional investors of Syndax Pharmaceuticals include BlackRock Inc. (10.18%), Bank of America Corp DE (4.57%), Elmind Capital LP (2.09%) and Trails Edge Capital Partners LP (1.25%). Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher and Nicholas AJ Botwood. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2026Today9/18/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 9 days, SNDX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees298Year Founded2005Price Target and Rating Average Price Target for Syndax Pharmaceuticals$42.30 High Price Target$57.00 Low Price Target$33.00 Potential Upside/Downside+140.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$285.42 million Net Margins-87.52% Pretax Margin-87.52% Return on Equity-372.94% Return on Assets-39.11% Debt Debt-to-Equity Ratio38.95 Current Ratio6.77 Quick Ratio6.44 Sales & Book Value Annual Sales$172.35 million Price / Sales9.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book23.81Miscellaneous Outstanding Shares88,610,000Free Float84,357,000Market Cap$1.56 billion OptionableOptionable Beta0.37 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SNDX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
